Phase 1 clinical trial of APG777, a fully optimized, subcutaneous, extended half-life anti-IL-13 antibody, initiated ahead of schedule with initial…
Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of…
Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple…
Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash (an…
No Material Impact on 2023 Financial Results; Reaffirms 2023 Outlook No Impact on Cash or Business Operations MURRAY, Utah, Nov.…
- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq:…
STOCKHOLM, SE / ACCESSWIRE / November 13, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB (publ.) is pleased to announce…
VANCOUVER, BC / ACCESSWIRE / November 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to…
This Revolution in the Health & Wellness Industry will Help People Get Exactly what they are Looking For instead of…
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of…